Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.55
+$0.26 · +3.14%
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Previous close
$8.55
+$0.26 · +3.14%
After-hours
$8.55
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Day range
Current $8.55
52-week range
Current $8.55
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
82
Deep Value
Sentiment
75
Bullish
Risk
36
Moderate Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Day range
Current $8.55
52-week range
Current $8.55
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 874.84M USD | 450.71M USD | 331.41M USD | 270.83M USD | 157.17M USD |
| Cost of goods sold | 19.08M USD | 12.49M USD | 4.66M USD | 6.59M USD | 7.26M USD |
| Gross profit | 855.76M USD | 438.23M USD | 326.75M USD | 264.23M USD | 149.91M USD |
| Research and development | 166.13M USD | 174.64M USD | 216.57M USD | 253.3M USD | 208.81M USD |
| Selling, general, and administrative | 348.65M USD | 266.13M USD | 213.89M USD | 159.37M USD | 118.82M USD |
| Operating expenses | 514.77M USD | 440.77M USD | 430.46M USD | 412.67M USD | 327.63M USD |
| Interest income | 10.67M USD | 14.75M USD | 15.78M USD | 5.13M USD | 62K USD |
| Interest expense | 78.87M USD | 98.52M USD | 108.24M USD | 99.09M USD | 59.29M USD |
| Depreciation and amortization | 1.39M USD | 1.25M USD | 1.66M USD | 1.44M USD | 777K USD |
| Operating income | 340.99M USD | −2.54M USD | −103.71M USD | −148.44M USD | −177.72M USD |
| Net income | 263.86M USD | −88.88M USD | −226.54M USD | −247.12M USD | −184.06M USD |
Company facts updated Oct 10, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI78.49M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI59.27M0.59%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM48.81M0.06%78.27B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB28.34M0.02%185.3B USD0.03%$289.48+0.64%
Vanguard Extended Market ETFVXF27.82M0.03%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO17.18M0.12%13.97B USD0.24%$356.78+0.94%
Vanguard Morningstar Small-Cap Growth ETFVBK16.24M0.04%44.7B USD0.05%$344.74+1.22%
iShares Biotechnology ETFIBB14.09M0.13%10.28B USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
